Biomarkers in small fiber neuropathy
-
Published:2022-12-30
Issue:6
Volume:2
Page:264-283
-
ISSN:
-
Container-title:Exploration of Neuroprotective Therapy
-
language:en
-
Short-container-title:Explor Neuroprot Ther
Author:
Chan Amanda C. Y.1ORCID, Ong Kathleen2ORCID, Ong Jonathan J. Y.1ORCID, Sharma Vijay K.1ORCID, Wong Hiu Yi3ORCID, Vijayan Joy1ORCID
Affiliation:
1. Department of Medicine, Division of Neurology, National University Hospital, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore 2. Yong Loo Lin School of Medicine, National University of Singapore, Singapore 3. Division of Life Science, State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology, Hong Kong, China; Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China
Abstract
Small fiber neuropathy (SFN) is a relatively common, but largely understudied neurological syndrome which has affected the lives of many globally. The common symptoms of SFN include pain, dysesthesia, and autonomic dysfunction, which are caused by damage to small nerve fibers. Due to its heterogeneous nature, SFN causes a multitude of symptoms which makes the disease and its subtypes difficult to diagnose. Furthermore, as the pathophysiology of SFN remains largely enigmatic, no cause is found in around 50% of the cases and these are classified as idiopathic SFN (iSFN). The difficult task of diagnosing SFN, and the even more elusive feat of hunting for the underlying etiology, demands accurate, precise, preferably noninvasive, and affordable tools, or a combination of them. Accordingly, appropriate biomarkers for SFN are needed to stratify patients and develop cause-centered treatments in addition to symptomatic treatments. As peripheral axons grow and repair, identifying underlying causes of SFN and intervening early may spur axonal regeneration in young patients, which can greatly improve their symptoms and improve quality of life. This narrative review aims to objectively highlight functional, histological, and molecular biomarkers to aid clinicians in discerning the diagnostic tests they should use to diagnose, confirm and determine the etiology of SFN. The strengths and limitations of each potential biomarker will be discussed. Clearer diagnostic criteria, guidelines, and work-up for SFN are required for clinicians to better identify the disease in patients presenting with non-specific symptoms.
Funder
Ministry of Health -Singapore
Publisher
Open Exploration Publishing
Subject
Marketing,Pharmacy,Health Policy,Pharmaceutical Science,Pharmacology,Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,Drug Discovery,Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,Pharmacology,Pharmacology,Toxicology,Pharmacology
Reference111 articles.
1. Cazzato D, Lauria G. Small fibre neuropathy. Curr Opin Neurol. 2017;30:490–9. 2. Lauria G, Morbin M, Lombardi R, Capobianco R, Camozzi F, Pareyson D, et al. Expression of capsaicin receptor immunoreactivity in human peripheral nervous system and in painful neuropathies. J Peripher Nerv Syst. 2006;11:262–71. 3. Wilder-Smith EP, Ong WY, Guo Y, Chow AW. Epidermal transient receptor potential vanilloid 1 in idiopathic small nerve fibre disease, diabetic neuropathy and healthy human subjects. Histopathology. 2007;51:674–80. 4. Chang CH, Chang YS, Hsieh YL. Transient receptor potential vanilloid subtype 1 depletion mediates mechanical allodynia through cellular signal alterations in small-fiber neuropathy. Pain Rep. 2021;6:e922. 5. Peters MJ, Bakkers M, Merkies IS, Hoeijmakers JG, van Raak EP, Faber CG. Incidence and prevalence of small-fiber neuropathy: a survey in the Netherlands. Neurology. 2013;81:1356–60.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|